Masimo's smartSET™ FDA Clearance Offers Breakthrough Innovation in Pulse Oximetry to Help Improve Critical Patient Outcomes
Industry-Leading Pulse Oximetry Platform Now Features First-of-Its-Kind Atrial Fibrillation (AFib) Detection with Previously Cleared AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection Designed Together to Deliver Earlier Clinical Insights IRVINE, Calif., Oct. 17, 2026...
Read the full story on PR Newswire → Opens the original article on www.prnewswire.comSummary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.